To sum up, in the pre-osimertinib era, in the treatment of lung cancer patients with common EGFR mutations (L858R and exon del19), the choice of a first or second-generation EGFR TKI depends on toxicity profile, physician’s preference, and the local availability of each agent. The gene discussed is EGFR; the disease is lung cancer.